R288
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 89
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.450
- PROTEIN_SECRETION+0.360
- OXIDATIVE_PHOSPHORYLATION+0.350
- SPERMATOGENESIS+0.240
- FATTY_ACID_METABOLISM+0.230
- MITOTIC_SPINDLE+0.150
- MYC_TARGETS_V1+0.130
- MTORC1_SIGNALING+0.110
- ANDROGEN_RESPONSE+0.100
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- ANGIOGENESIS-0.490
- TNFA_SIGNALING_VIA_NFKB-0.490
- HYPOXIA-0.470
- HEDGEHOG_SIGNALING-0.430
- P53_PATHWAY-0.430
- COAGULATION-0.420
- IL6_JAK_STAT3_SIGNALING-0.420
- MYOGENESIS-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R320 | — | — | 0.934 |
| 2 | R391 | — | — | 0.916 |
| 3 | TCGA-QK-A8ZA-01A-11R-A39I-07 | — | — | 0.892 |
| 4 | R356 | — | — | 0.891 |
| 5 | 20040104.LumB | — | B | 0.891 |
| 6 | SRR1516065 | — | — | 0.889 |
| 7 | fd49c74b-2a85-46cd-aaa0-dbd2f1284947 | — | — | 0.878 |
| 8 | R150 | — | — | 0.878 |
| 9 | TCGA-CR-6472-01A-11R-1873-07 | — | — | 0.877 |
| 10 | SRR12202430 | — | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.070 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.030 | Idelalisib | — uncovered |